Pathogenic variants in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 by altering the BSEP protein, responsible for exporting bile salts from hepatocytes. Its deficiency causes toxic accumulation of bile acids, progressive liver damage, and, in severe forms, liver failure from infancy.
Familial intrahepatic cholestasis (ABCB11 gene)
ABCB11-related familial intrahepatic cholestasis is also known as progressive familial intrahepatic cholestasis type 2 (PFIC2) or BSEP deficiency. It is inherited in an autosomal recessive pattern: two pathogenic variants, one on each copy of the gene, are typically required to develop the classic form. ABCB11 encodes the bile salt export pump (BSEP), a canalicular protein that transports bile salts from hepatocytes into bile.
When BSEP does not function properly, bile acids are retained in the liver and damage hepatocytes, causing cholestasis, inflammation, fibrosis, and cirrhosis. Unlike PFIC3, PFIC2 typically presents with normal or low GGT. The global incidence of familial intrahepatic cholestases is estimated to be between 1 in 50,000 and 100,000 births. Severe biallelic variants in ABCB11 are also associated with an increased risk of hepatobiliary tumors, especially hepatocellular carcinoma.
Symptoms
The symptoms usually appear in the first few months of life. The most characteristic sign is intense and persistent itching, which can seriously affect the quality of life. Cholestasis can manifest with recurrent or sustained jaundice, pale stools, dark urine, hepatomegaly, and growth retardation. Complications due to malabsorption and deficiency of fat-soluble vitamins (A, D, E, and K), as well as progression to cirrhosis, portal hypertension, liver failure, or liver cancer, may also appear.
Disease management
Management aims to reduce biliary toxicity, control pruritus, and prevent the progression of liver damage. It includes follow-up by hepatology, nutritional support, and supplementation with fat-soluble vitamins. Ursodeoxycholic acid (UDCA) can be used, although the response is often variable in PFIC2. For pruritus, drugs such as rifampicin or cholestyramine are used, and in certain patients, ileal bile acid transporter (IBAT/ASBT) inhibitors. If medical treatment is insufficient, biliary diversion or liver transplantation may be considered in or refractory cases.
Genes analyzed
Bibliography
A Siddiqi I, Tadi P. Progressive Familial Intrahepatic Cholestasis. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
Vitale G, Mattiaccio A, Conti A, et al. Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers (Basel). 2022 Jul 14;14(14):3421.
